4′-Ethynyl nucleoside analogs: Potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 5, 2001, Pages 1539-1546

  Kodama, E I ^a   Kohgo, S ^a   Kitano, K ^a   Machida, H ^a   Gatanaga, H ^a   Shigeta, S ^a   Matsuoka, M ^a   Ohrui, H ^a   Mitsuya, H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' AMINO 3' DEOXYTHYMIDINE; DEOXYADENOSINE; DEOXYCYTIDINE; NUCLEOSIDE ANALOG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYRIBONUCLEOSIDE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION; DRUG ANTAGONISM; DRUG INTERACTION; DRUG STABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; DEOXYRIBONUCLEOSIDES; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG STABILITY; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0034744423     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.5.1539-1546.2001     Document Type: Article

References (42)

1. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase
2. Preclinical evaluation of MKC-422, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro
3. Factors influencing the inhibition of repair of irradiation-induced DNA damage by 2′-deoxycoformycin and deoxyadenosine
4. Selective action of 4′-azidothymidine triphosphate on reverse transcriptase of human immunodeficiency virus type 1 and human DNA polymerases alpha and beta
5. A proposed mechanism of action of 1-β-D-arabiofuranosylcytosine as an inhibitor of the growth of leukemic cells
6. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRT1s) in the therapy of HIV-1 infection
7. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication By a class of bicyclams interacting with a viral uncoating event
8. The reversal of cytosine arabionoside activity in vivo by deoxycytidine
9. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
10. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection
11. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
12. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
13. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
14. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene
15. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method
16. Synthesis of 4′-C-ethynyl-beta-Darabino and 4′-C-ethynyl-2′-deoxy-beta-D-ribo-pentofuranosyl pyrimidines, and their biological evaluation
17. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
18. Solid-state and solution conformations of the potent HIV inhibitor, 4′-azidothymidine
19. Synthesis and anti-HIV activity of 4′-azido- and 4′-methoxynucleosides
20. Evolution and fitness of HIV-1 with the po1 gene mutations conferring multi-dideoxynucleoside resistance
21. Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2′,3′-dideoxynucleosides in vitro
22. Strategies for antiviral therapy in AIDS
23. Discovery and development of antiretroviral therapeutics for HIV infection
24. Dextran sulfate suppression of viruses in the HIV family: Inhibition of virion binding to CD4+ cells
25. Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV
26. 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
27. Nucleosides and nucleotides. 185. Synthesis and biological activities of 4′alpha-C-branched-chain sugar pyrimidine nucleosides
28. Synthesis of 4′-C-ethynyl-β-Darabino- and 4′-C-ethynyl-2′-deoxy-β-D-ribo-pentofuranosyl pyrimidines and purines and evaluation of their anti-HIV-1 activity
29. Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative
30. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
31. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids
32. Touching the heart of HIV-1 drug resistance: The fingers close down on the dNTP at the polymerase active site
33. Antiretroviral treatment for HIV infection
34. Protection by various deoxynucleosides against deoxyadenosine-induced DNA damage in adenosine deaminase-inactivated lymphocytes
35. Emergence of human immunodeficiency virus type-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
36. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: An in vitro comparative study
37. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
38. Nucleosides and nucleotides. 183. Synthesis of 4′alpha-branched thymidines as a new type of antiviral agent
39. In vitro induction of human immunodeficiency virus type 1 variants resistant to 2′-beta-fluoro-2′,3′-dideoxyadenosine
40. Public health implications of antiretroviral therapy and HIV drug resistance
41. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
42. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1